

RECEIVED
CENTRAL FAX CENTER

DEC 09 2005

PATENT
Atty. Dkt. No. 054707-0661

MS AF
Expedited Procedure Requested
GAU 1624

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Yong-Qian Wu *et al.*
Title: AZA COMPOUNDS, PHARMACEUTICAL
COMPOSITIONS AND METHODS OF USE
Appl. No.: 09/835,523
Filing Date: 04/17/2001
Examiner: Tamthom Ngo Truong
Art Unit: 1624

**CERTIFICATE OF FACSIMILE
TRANSMISSION**
I hereby certify that this paper is being facsimile
transmitted to the United States Patent and
Trademark Office, Alexandria, Virginia on the
date below.
Rouget F. Henschel
(Printed Name)
[Signature]
(Signature)
1-DEC-2005
(Date of Deposit)

SECOND AMENDMENT AND REPLY UNDER 37 CFR 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This communication responds to the Final Office Action dated March 25, 2005. A response was filed September 26, 2005, with a Notice of Appeal and a Terminal Disclaimer, and a check of \$825.00 for fees. The Office mailed an Advisory Action on October 18, 2005, indicating that the amendments in the response would not be entered because claims 7-10 remained rejected. However the Office indicated claims 1-4 and 48 were allowable. This Second Amendment and Reply Under 37 CFR 1.116 is now submitted after an Examiner Interview of November 28, 2005, where the Examiner agreed to consider proposed amendments to claims 7-10.

12/12/2005 TL0111 00000067 190741 09835523

01 FC:1251 120.00 DA

Applicants have enclosed with this amendment a Petition for Extension of Time to make this response timely.

The PTO did not receive the following
listed item(s) Check

USPTO
TO: Central Fax COMPANY:
12/01/2005 17:34 FAX

12/9/2005 11:11 AM PAGE 6/042 Fax Server

005/041

Application. No. 09/835,523
Atty. Dkt. No. 054707-0661
Response To Final Office Action Of 03-25-2005

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this document. This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, is presented, with an appropriate defined status identifier.

Remarks begin on page 34 of this document.